1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Japan's Price Cuts Slated For April Bring Old, New Blues For Industry

Xolair, Lixiana, Keytruda Hard Hit

 
• By Ian Haydock

Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.

Japan
Latest Japan Price Cut To Hit In April • Source: Shutterstock

Japan’s next regular revision of drug reimbursement prices will see an average cut of around 4.4% across the pharma industry, although the impact by individual company varies widely according to discounting practices and product mix, ranging between 1-9%.

The new tariff prices under the country’s universal national health insurance (NHI) scheme will come into effect on 1 April, and as usual follow a comprehensive survey last October of actual

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.